DE602004009306D1 - 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern - Google Patents

3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern

Info

Publication number
DE602004009306D1
DE602004009306D1 DE602004009306T DE602004009306T DE602004009306D1 DE 602004009306 D1 DE602004009306 D1 DE 602004009306D1 DE 602004009306 T DE602004009306 T DE 602004009306T DE 602004009306 T DE602004009306 T DE 602004009306T DE 602004009306 D1 DE602004009306 D1 DE 602004009306D1
Authority
DE
Germany
Prior art keywords
chinolin
dihydro
derivatives
norepinephrine
recovery inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004009306T
Other languages
English (en)
Other versions
DE602004009306T2 (de
Inventor
Nicholas Paul Camp
Roberta Penariol
Christopher David Beadle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602004009306D1 publication Critical patent/DE602004009306D1/de
Application granted granted Critical
Publication of DE602004009306T2 publication Critical patent/DE602004009306T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE602004009306T 2003-04-25 2004-04-16 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern Expired - Fee Related DE602004009306T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0309440.6A GB0309440D0 (en) 2003-04-25 2003-04-25 Quinolone derivatives
GB0309440 2003-04-25
US47727703P 2003-06-10 2003-06-10
US477277P 2003-06-10
PCT/US2004/009290 WO2004096773A1 (en) 2003-04-25 2004-04-16 Quinolone derivatives

Publications (2)

Publication Number Publication Date
DE602004009306D1 true DE602004009306D1 (de) 2007-11-15
DE602004009306T2 DE602004009306T2 (de) 2008-07-10

Family

ID=9957218

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004009306T Expired - Fee Related DE602004009306T2 (de) 2003-04-25 2004-04-16 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern

Country Status (9)

Country Link
US (1) US20070105845A1 (de)
EP (1) EP1622874B1 (de)
JP (1) JP2006524689A (de)
AT (1) ATE374751T1 (de)
CA (1) CA2518753A1 (de)
DE (1) DE602004009306T2 (de)
ES (1) ES2293313T3 (de)
GB (1) GB0309440D0 (de)
WO (1) WO2004096773A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569608A (en) * 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
WO2008093737A1 (ja) 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. アミド誘導体
CA2765527A1 (en) 2009-06-24 2010-12-29 Satoshi Suetsugu N-substituted-cyclic amino derivative
AU2013308081A1 (en) * 2012-08-27 2015-02-26 Lupin Atlantis Holdings Sa Arylalkylamine compounds as calcium sensing receptor modulators
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696555B2 (ja) * 1986-07-31 1994-11-30 大塚製薬株式会社 カルボスチリル誘導体
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU769430B2 (en) * 1999-10-13 2004-01-29 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
EP1395253A2 (de) * 2000-11-15 2004-03-10 Eli Lilly And Company Behandlung von angstzuständen
GB0112122D0 (en) * 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
AU2003298664A1 (en) * 2002-11-20 2004-06-15 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'

Also Published As

Publication number Publication date
CA2518753A1 (en) 2004-11-11
ES2293313T3 (es) 2008-03-16
WO2004096773A1 (en) 2004-11-11
US20070105845A1 (en) 2007-05-10
EP1622874A1 (de) 2006-02-08
JP2006524689A (ja) 2006-11-02
ATE374751T1 (de) 2007-10-15
EP1622874B1 (de) 2007-10-03
DE602004009306T2 (de) 2008-07-10
GB0309440D0 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ATE433447T1 (de) Pyrimiidinverbindungen
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20054787D0 (no) Indenderivater som farmasotiske midler
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
SE0302760D0 (sv) New compounds
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
ATE440833T1 (de) Antithrombotische diamide
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
SE0300119D0 (sv) Novel compounds
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
SE0201544D0 (sv) Novel compounds and thier use
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
SE0302139D0 (sv) Novel compounds
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
ATE517623T1 (de) Verwendung von methylphenidat-derivaten
SE0303280D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee